Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

10 Feb 2026 - 13 Feb 2026
17 Apr 2026 - 21 Apr 2026

Feasibility of Tuberculosis Test Proven in Low-Resource Settings

By LabMedica International staff writers
Posted on 10 May 2011
A molecular diagnostic test for tuberculosis (TB) has proven to be both effective and rapid in countries in the developing world that are endemic for the disease.

The assay is a real time polymerase chain reaction (rt-PCR) amplification test that simultaneously detects rifampicin resistance and is used in conjunction with an automated platform, which integrates sample processing and greatly simplifies testing.

A multicenter study is being conducted under the auspices of the Foundation for Innovative New Diagnostics (FIND; Geneva, Switzerland).

South African participants at the University of Cape Town (Cape Town, South Africa), and others from Peru, India, Azerbaijan, the Philippines, and Uganda, enrolled 6,648 eligible adults. More...
The study groups were all aged 18 years or older, with at least two weeks of cough who presented consecutively to urban or periurban primary-care health centers from August 11, 2009, until June 26, 2010. The primary impact outcomes assessed were the time between the first presentation to clinic of a patient with symptoms and the start of appropriate treatment for TB and, secondly, the proportion of patients in each site with undiagnosed TB, two months after the first TB test.

The rt-PCR assay is an automated cartridge based diagnostic system, known as the Xpert MTB/RIF, and was developed for the GeneXpert platform (Cepheid, Sunnyvale, CA, USA). The test correctly detected tuberculosis in more than 90% of patients with positive cultures, with a 99% specificity for nontuberculosis samples. Performance was much the same during validation and implementation phases. A onetime MTB/RIF test identified significantly more cases of tuberculosis than did 2-3 smear microscopy examinations per patient, which detected 699 of 1,041 culture-positive patients and 3,700 of 3,718 patients without tuberculosis. The sensitivity of the MTB/RIF assay was not significantly affected by human immunodeficiency virus (HIV) coinfection status, which significantly decreased the sensitivity of smear microscopy.

The authors concluded that overall, their findings suggest that decentralized MTB/RIF test implementation is feasible and could lead to an improvement in tuberculosis care and control. Any improvement will require increased detection of tuberculosis and multidrug-resistant-tuberculosis to coincide with scale-up of first-line, and more importantly, second-line treatment. Whether early and appropriate treatment after MTB/RIF testing can reduce tuberculosis-associated morbidity and mortality, and its effect on transmission, still needs to be established. The study was published on April 30, 2011, the Lancet.

Related Links:
Foundation for Innovative New Diagnostics
University of Cape Town
Cepheid


Gold Member
Hybrid Pipette
SWITCH
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Hematology Analyzer
Medonic M32B
Silver Member
PCR Plates
Diamond Shell PCR Plates
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.